Русский
The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-naïve patients with benign prostatic hyperplasia
DOI: https://dx.doi.org/10.18565/urology.2019.3.36-42
Yu.A. Kupriyanov, P.I. Rasner, I.M. Rokhlikov, A.A. Akrikidi, V.V. Soloviev, A.A. Markov, E.V. Nozdrin, L.A. Logvinov, R.P. Vasilevskiy, K.S. Skrupskiy, D.Yu. Pushkar, M.A. Putilovskiy, O.I. Epstein
1 A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia, Moscow, Russia; 2 Municipal clinical hospital named after S.I. Spasokukotskiy, Moscow, Russia; 3 NPF «Materia Medica Holding» LTD, Moscow, Russia; 4 Research Institute of General Pathology and Pathophysiology, Moscow, Russia; 5 GBUZ CP № 68 of Moscow Health Department; 6 GBUZ CP № 29 of Moscow Health Department; 7 GBUZ CP № 170 of Moscow Health Department; 8 GBUZ CP №107 of Moscow Health Department; 9 GBUZ CP 201 of Moscow Health Department;10 GBUZ CP №69 of Moscow Health Department; 11 GBUZ CP №134 of Moscow Health Department
Introduction. Benign prostatic hyperplasia (BPH) is one of the most common diseases in men over 50 years. The prevalence of the BPH increases with age, and pathologic features of BPH are found in about 90% of men over 80 years.
Aim. The aim of the study was to study the efficacy and safety of Afalaza for the treatment of lower urinary tract symptoms (LUTS) in treatment-naïve patients with BPH.
Materials and methods. A multicenter study of using Afalaza for the treatment of LUTS in treatment-naïve patients with BPH was carried out in 9 urological centers in Moscow. A total of 80 treatment-naïve patients with BPH were enrolled. The improvement in the total score of IPSS, IIEF-5 and QoL after 30 weeks of therapy was evaluated as well as changes in prostate volume and maximum urinary flow rate (Qmax).
Results. After 30 weeks of therapy, there was a significant decrease in the total IPSS score. A decrease in the total IPSS score by 5.5 points (+37.9%) from 14.5±4.0 at the baseline to 9.0±4.1 at the visit 9 was seen. The QoL decreased by 1.8 (-38.3%) points from 4.7±1.0 at the baseline. The Qmax also changed from 12.7±4.6 to 16.4±5.7 (+28.3%) after 30 weeks of therapy. At the visit 9, the total IIEF5 score increased by 3.4±4.4 (+19.9%) from 17.1±4.3 at the baseline. In addition, prostate volume decreased from 42.7±11.1 at baseline to 41.0±9.8 cc post-treatment (-5.15%). A reduction of post-void residual urine volume from 26.0±25.3 at baseline to 17.7±24.2 (-31.9%) post-treatment was also shown.
Conclusion. The results of a multicenter study demonstrate the efficacy of Afalaza for treatment of treatment-naïve patients with LUTS/BPH. Afalaza reduces prostate volume and improves an erectile function.
Aim. The aim of the study was to study the efficacy and safety of Afalaza for the treatment of lower urinary tract symptoms (LUTS) in treatment-naïve patients with BPH.
Materials and methods. A multicenter study of using Afalaza for the treatment of LUTS in treatment-naïve patients with BPH was carried out in 9 urological centers in Moscow. A total of 80 treatment-naïve patients with BPH were enrolled. The improvement in the total score of IPSS, IIEF-5 and QoL after 30 weeks of therapy was evaluated as well as changes in prostate volume and maximum urinary flow rate (Qmax).
Results. After 30 weeks of therapy, there was a significant decrease in the total IPSS score. A decrease in the total IPSS score by 5.5 points (+37.9%) from 14.5±4.0 at the baseline to 9.0±4.1 at the visit 9 was seen. The QoL decreased by 1.8 (-38.3%) points from 4.7±1.0 at the baseline. The Qmax also changed from 12.7±4.6 to 16.4±5.7 (+28.3%) after 30 weeks of therapy. At the visit 9, the total IIEF5 score increased by 3.4±4.4 (+19.9%) from 17.1±4.3 at the baseline. In addition, prostate volume decreased from 42.7±11.1 at baseline to 41.0±9.8 cc post-treatment (-5.15%). A reduction of post-void residual urine volume from 26.0±25.3 at baseline to 17.7±24.2 (-31.9%) post-treatment was also shown.
Conclusion. The results of a multicenter study demonstrate the efficacy of Afalaza for treatment of treatment-naïve patients with LUTS/BPH. Afalaza reduces prostate volume and improves an erectile function.
About the Autors
Corresponding author: Yu.A. Kupriyanov – Ph.D., assistant at the Department of Urology of A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia, urologist at the Municipal clinical hospital named after S.I. Spasokukotskiy, Moscow, Russia; e-mail: Dr.kupriyanov@gmail.com
Similar Articles
